Company / R&D Expense
Halozyme R&D Expense History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D Expense
$81.5M
FY2025
5-year range
$66.6M / $140.8M
FY2021-FY2025
Trend
+3.1%
vs FY2024
Sector context
#153 of 210
Health Care
What the data says
At $81M, Halozyme's r&d expense ranks #153 of 210 in the Health Care sector. R&D Expense has increased for 3 consecutive years, from $67M in FY2022 to $81M in FY2025.
Based on SEC 10-K filings.
$81M in FY2025 with a 5-year CAGR of -11.5%.
Improved from $76M to $81M over the past 2 years.
Health Care sector context is included.
R&D Expense over time
Growth rates
- 3-Year CAGR
- +7.0%
- 5-Year CAGR
- -11.5%
- 10-Year CAGR
- -
Sector benchmark
#153 of 210 in Health CareTop 73% of 210This company $81.5M Sector average $644.0M
▼
-87.3% below sector average
Key checks
Key Insights
- Halozyme's r&d expense has grown for 3 consecutive years.
- 5-year CAGR of -11.5%, indicating a declining trend.
- In FY2025, r&d expense increased 3.1% year-over-year.
- Ranks #153 out of 210 companies in the Health Care sector.
Company context
Key Data Points
- Strong profit margin: 47.9%
- High earnings quality (cash-backed earnings)
- Strong return on equity: 118.2%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $81.5M | +3.1% |
| FY2024 | $79.0M | +3.5% |
| FY2023 | $76.4M | +14.6% |
| FY2022 | $66.6M | -52.7% |
| FY2021 | $140.8M | -6.3% |
| FY2020 | $150.3M | -0.3% |
| FY2019 | $150.6M | +0.3% |
| FY2018 | $150.3M | -0.3% |
| FY2017 | $150.6M | +89.0% |
| FY2016 | $79.7M | -17.5% |
As of FY2025 · SEC 10-K · Updated Jun 30, 2026